Full-Time
AI-driven documentation automation for life sciences
$150k - $300k/yr
San Francisco, CA, USA
In Person
See people who can refer or advise you
Collate provides an AI-powered platform that automates the creation and management of documentation for drug development, medical devices, and diagnostics. It works by generating, organizing, and governing regulatory and quality documents while offering data discovery and governance tools to ensure high-quality data assets. It distinguishes itself by offering an end-to-end, life-sciences–focused solution that covers drug, device, and diagnostic workflows in one platform, reducing manual work and speeding up approvals. Its goal is to shorten development and regulatory timelines so researchers can focus on discovery and bring life-saving innovations to patients faster.
Company Size
11-50
Company Stage
Series B
Total Funding
$125M
Headquarters
San Francisco, California
Founded
2025
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Company Equity
Flexible Work Hours
Professional Development Budget
Surbhi Sarna, CEO and founder of Collate, discussed her company's AI-native software that automates documentation for life-sciences companies bringing drugs and devices to market. The GxP-compliant platform maintains human oversight for audits. Sarna's journey into healthcare technology began as a teenager when she was hospitalised with debilitating ovarian cysts, facing uncertainty about whether she had cancer. This experience motivated her to found nVision Medical, which was later acquired by Boston Scientific. Collate addresses the extensive documentation requirements in the pharmaceutical and medical device industries, streamlining regulatory compliance processes whilst ensuring proper human verification remains in place.
AI startup Collate has raised $95 million in a Series C round led by Redpoint Ventures, valuing the company at nearly $1 billion. The funding brings total capital raised to $125 million since the San Francisco-based company emerged from stealth 17 months ago. Founded by two-time entrepreneur and former Y Combinator partner Surbhi Sarna, Collate automates paperwork for life sciences companies, including regulatory filings and clinical trial documentation. The startup has signed approximately 50 customers since May 2025, including major pharmaceutical companies and medical device manufacturers. Collate's AI tools deliver time savings of 50% to 90% on documents that previously took months to complete, whilst maintaining accuracy above 90%. The company requires human verification before documents are exported to ensure patient safety.
Biotech startup Collate, founded by Surbhi Sarna, has secured a $30 million seed fund to automate paperwork in the life sciences industry using AI. The funding round was led by Redpoint, with participation from First Round, Conviction Partners, and YC, valuing Collate at over $100 million. Collate aims to streamline documentation for diagnostic, medical device, and drug development companies, enhancing R&D and reducing time to market. Co-founders Nate Smith and Jigish Patel bring additional expertise.
Y Combinator's Surbhi Sarna has raised $30 million for Collate, a startup aiming to automate the tedious parts of running a life sciences business using AI.